Clinical trials: Advanced Disease
Oropharyngeal Cancer
A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
To determine 2-year local (primary tumor site) control and toxicity rates in patients receiving adjuvant RT post-TORS, omitting the primary tumor bed, in patients with completely resected, HPV-positive SCCA of the oropharynx.
- Trial name
- NCT02159703
- Testing
- TORS, Adjuvant Radiation Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced…
- Trial name
- NCT07474727
- Testing
- AMT-676, 5-FU, Leucovorin
- Where
- 19 sites in China
- Volunteers
- 180 people
- Sponsor
- Multitude Therapeutics Inc.
Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help solid tumor cells develop into normal cells.
- Trial name
- NCT00008086
- Testing
- calcitriol, carboplatin
- Where
- United States
- Sponsor
- University of Pittsburgh
Stomach Neoplasms
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not…
- Trial name
- NCT00555620
- Testing
- capecitabine, oxaliplatin, sunitinib malate
- Where
- 3 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
The trial will be performed to evaluate whether BI 2536 may be effective in the treatment of advanced or metastatic NSCLC of stage IIIB or IV in patients who relapsed after or failed first-line therapy.
- Trial name
- NCT00376623
- Testing
- BI 2536
- Where
- 7 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced Rectal Cancer, Electrochemotherapy
Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant electrochemotherapy on locally advanced rectal cancer (UICC II-III) in an intended curative clinical setting, using an endoscopic electroporation…
- Conditions
- Locally Advanced Rectal Cancer, Electrochemotherapy, Neoadjuvant Therapy, Down Staging
- Trial name
- nECT (NCT03040180)
- Testing
- Electrochemotherapy with bleomycin, EndoVE
- Where
- 2 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- Zealand University Hospital
Melanoma
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
The purpose of this study is to assess the safety and efficacy of the combination of IMM-101 with nivolumab.
- Trial name
- NCT03711188
- Testing
- Nivolumab, Ipilimumab, IMM-101
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Immodulon Therapeutics Ltd
Ovarian Cancer, Ovarian Carcinoma
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer
- Trial name
- NCT03748186
- Testing
- STRO-002
- Where
- 27 sites in United States, Spain
- Volunteers
- 136 people
- Sponsor
- Sutro Biopharma, Inc.
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty
Immune Aging and Advanced Therapy Outcomes in Older Adults With IBD
The goal of this observational study is to learn whether signs of immune aging and frailty can help predict the balance of benefits and risks of advanced therapies in adults aged 60 years or older with inflammatory bowel disease…
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty, Immunosenescence
- Trial name
- NCT07828886
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients.
- Conditions
- Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
- Trial name
- NCT05941741
- Testing
- Intensity Modulated Radiation Therapy, Chemotherapy, Immune checkpoint inhibitor
- Where
- 3 sites in China
- Volunteers
- 380 people
- Sponsor
- Sun Yat-sen University
Advanced Cancer, Brain Involvement
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in human xenograft intracerebrally implanted tumor mouse models, acceptable preclinical toxicities in mouse, rat and…
- Trial name
- DM-CHOC-PEN (NCT01048008)
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- DEKK-TEC, Inc.
Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with limited therapeutic options and a five-year survival rate below 10 % in advanced stages.
- Trial name
- ResCPa (NCT07153289)
- Testing
- CD318-CAR-T cells
- Volunteers
- 38 people
- Sponsor
- University Hospital Tuebingen
Breast Neoplasms
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC)…
- Trial name
- NCT06926868
- Testing
- Iza-bren, Nab-paclitaxel, Paclitaxel
- Where
- 295 sites in United States, Argentina and 26 more
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
The purpose of this study is to determine if the combination therapy of Hormone, Paclitaxel and Radiation therapy are effective in treatment of locally advanced prostate cancer
- Trial name
- NCT02911350
- Testing
- Hormone Suppressors, Paclitaxel, Radiation Therapy
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Invasive Breast Cancer
Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
This study will evaluate the rate of pathological complete response (pCR) to the sequential therapy of Doxil, paclitaxel, and cyclophosphamide with concurrent Avastin for patients with locally advanced invasive (T2,T3, Nany, M0)…
- Trial name
- NCT00635050
- Testing
- Doxil, Paclitaxel, Cyclophosphamide, Avastin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Prostate Cancer
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
- Trial name
- NCT00841113
- Testing
- Abarelix, Goserelin plus Bicalutamide
- Volunteers
- 177 people
- Sponsor
- Speciality European Pharma Limited
Breast Cancer, Liver Cancer
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical…
- Conditions
- Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- ESCAT (NCT06958224)
- Testing
- Large and early multigene sequencing
- Where
- France
- Volunteers
- 360 people
- Sponsor
- University Hospital, Lille
Angina
Shockwave Treatment for Advanced Angina in Maastricht
There is an increasing number of patients with a coronary anatomy that does not allow additional revascularization procedures, while the patients suffer from angina pectoris at rest or at minimal exercise levels despite optimised…
- Trial name
- SWAAM (NCT01361659)
- Testing
- shockwave treatment
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Maastricht University Medical Center
Rectal Cancer
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer
The goal of this clinical trial is to learn if neoadjuvant Fruquintinib and Tislelizumab combined with mCapeOX works to treat mid-high pMMR/MSS locally advanced rectal cancer patients compared with CapeOX.
- Trial name
- PKUCH-R09 (NCT06443671)
- Testing
- CapeOX, Fruquintinib and Tislelizumab combined with mCapeOX
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Peking University Cancer Hospital & Institute
Pancreatic Cancer
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer.
- Trial name
- NCT00276744
- Testing
- cetuximab, capecitabine, docetaxel
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.